Categories: world

Global study predicts more than 20 percent increase in insulin use by 2030

Credit: CC0 Public DomainThe amount of insulin needed to effectively treat Type 2 diabetes will increase by more than 20%…



Credit: CC0 Public Domain

The amount of insulin needed to effectively treat Type 2 diabetes will increase by more than 20% worldwide over the next 12 years, but without major asset improvements, insulin will be out of reach of approximately half of the 79 million adults with type 2 diabetes who need it in 2030, according to a new model study published in The Lancet Diabetes & Endocrinology journal.

The findings are of particular importance to the African, Asian and Oceania regions as the study predicts will have the largest unpredictable insulin requirement in 2030 if availability remains at current levels.

The analysis underlines the importance of dealing with barriers to the insulin market, especially in Africa. The authors warn that strategies for making insulin more accessible and affordable will be crucial to ensuring that demand is met.

“These estimates indicate that current levels of insulin access are very insufficient compared with estimated needs, especially in Africa and Asia, and more efforts should be devoted to overcoming this threatening health problem,” said Dr. Sanjay Basu of Stanford University, USA. led the research.

“Despite the UN’s commitment to treating non-communicable diseases and ensuring universal access to drugs for diabetes worldwide, insulin is hardly and unnecessarily difficult for patients to access. The number of adults with type 2 diabetes is expected to fall below over the next 1

2 years due to aging, urbanization and related changes in diet and physical activity. Unless governments initiate initiatives to make insulin accessible and affordable, usage will always be far from optimal. ”

Insulin is essential for all people with type 1 diabetes and some type 2 diabetes patients to reduce the risk of complications such as blindness, amputation, renal failure and stroke. Since global rates for type 2 diabetes are rising and type 2 diabetes patients live longer (which increases insulin requirements), an overall picture of global insulin needs is required because insulin therapy is expensive and the international insulin market is dominated today by only three major manufacturers.

Using data from the International Diabetes Federation and 14 cohort studies (representing more than 60% of the world’s population with type 2 diabetes), researchers estimated the burden of type 2 diabetes in 221 countries and territories between 2018 and 2030. They estimated the potential number of insulin users, the amount of insulin required and the burden of diabetic complications at different levels of insulin access and treatment goals (from 6.5% to 8% HbA1c, a measure of blood sugar) in adults 18 years of age or older.

The results showed that worldwide, the number of adults with type 2 diabetes is expected to increase by more than one fifth from 406 million in 2018 to 511 million by 2030, with more than half living in just three countries, China (130 million), India 98 million) and the United States (32 million).

At the same time, global insulin consumption is expected to rise from 526 million 1,000 bottles in 2018 to 634 million by 2030, and will be highest in Asia (322 million bottles 2030) and lowest in Oceania (4 million).

The authors calculated that, compared to current levels of insulin access, if universal global access was achieved (with a HbA1c treatment target of 7% or less), the number of people with type 2 diabetes worldwide would use insulin 2030 double (from about 38 million [7.4% of all people with type 2 diabetes) to 79 million [15.5%]).

Estimates suggest that it would be greatest to make insulin available would have the greatest impact in the African region – Increasing insulin utilization 7-fold from approximately 700,000 people with type 2 diabetes at current levels of access to over 5 million while universal Access in Asia was more than double the number of insulin users from 21 million to 48 million people.

The study also predicts that with a higher glucose target of 8%, over the 75s, halve insulin use and prevent more disability by reducing severe hypoglycaemic events (more common in older adults) by 44% only a 20% increase in diabetes-related eye damage – kidney and nerve complications.

“Most guidelines recommend glucose targets of less than 6.5% or 7%. Targeting a more moderate threshold for control is likely to improve overall health by balancing the risks of hypoglycaemia with prolonged microvascular disease,” says Basu. 19659005] The authors note several limitations, including the fact that predictions for type 2 diabetes do not account for diet and physical activity change over time, which means that the disease may have a much greater or lesser impact in the future. They also note that they use The methods assume that the relationship between underlying demographics, treatment goals and complications is similar across the country, which may not represent ethnic variations.

Commenting on the consequences of the study, Dr. Hertzel Gerstein writes from McMaster University, Canada: “These extensive analyzes were explicitly different circumstances. Nevertheless, they are based on mathematical models, which in turn are based on other mathematical models. They are also based on a series of assumptions. Such considerations indicate that predictions about the future must be carefully considered. Regardless of these uncertainties, insulin will probably keep its place as an important treatment for type 2 diabetes and as such, sufficient global supply needs to be estimated and ensured. Ongoing updates to models such as those containing new data and trends as they may be the most reliable way to ensure their reliability and relevance to evidence-based care. “


Explore further:
WHO issues recommendations for Tx intensification in T2DM

More information:
Lancet Diabetes & Endocrinology (2018). www.thelancet.com/journals/lan … (18) 30303-6 / full text

Journal Reference:
Lancet Diabetes & Endocrinology

Provided by:
Lancet

Share
Published by
Faela